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SUMMARY
Approximately 10% of human colorectal cancer (CRC) are associated with activated BRAFV600Emu-
tation, typically in absence ofAPCmutation and often associatedwith a CpG islandmethylator (CIMP)
phenotype. To protect from cancer, normal intestinal epithelial cells respond to oncogenic
BRAFV600E by activation of intrinsic p53 and p16-dependent tumor suppressor mechanisms, such
as cellular senescence. Conversely, CIMP is thought to contribute to bypass of these tumor suppressor
mechanisms, e.g. via epigenetic silencing of tumor suppressor genes, such as p16. It has been repeat-
edly proposed that DNMT3B is responsible for BRAFV600E-induced CIMP in human CRC. Here we set
out to test this by in silico, in vitro, and in vivo approaches. We conclude that although both
BRAFV600E and DNMT3B harbor oncogenic potential in vitro and in vivo and show some evidence
of cooperation in tumor promotion, they do not frequently cooperate to promote CIMP and human
intestinal cancer.
INTRODUCTION
In normal cells, the BRAF kinase, encoded by the BRAF gene, is a critical effector of cell signaling pathways,
most notably the RAS-BRAF-MEK-ERK mitogenic pathway. This proto-oncogenic pathway is activated by
genetic mutations at some point along the cascade in most human cancers (Yaeger and Corcoran,
2019). Approximately 10% of human CRC are associated with activated BRAFV600Emutation. Although in-
hibitors of activated BRAF, such as Vemurafenib, are of some benefit in other cancers harboring
BRAFV600E, such as melanoma, in CRC these inhibitors are of limited therapeutic value (Dienstmann
et al., 2017). Yet CRC harboring BRAFV600E has a poor prognosis (Samowitz et al., 2005b; Ogino et al.,
2009). Thus, it is important to understand the oncogenic mechanisms underlying this disease.
Activated BRAFV600E mutation is typically found in absence of mutation in the Adenomatous Polyposis
Coli (APC) gene, a gene that is mutated and inactivated in 80% of CRC (Dienstmann et al., 2017). Acti-
vated BRAFV600E drives hyperproliferation and neoplasia via the MEK-ERK mitogenic pathway (Lavoie
and Therrien, 2015). However, to protect from cancer, normal intestinal epithelial cells are thought to
respond to oncogenic BRAFV600E by activation of intrinsic TP53 (p53) and CDKN2A (p16)-dependent tu-
mor suppressor mechanisms (Rad et al., 2013), including cellular senescence (Carragher et al., 2010; Kriegl
et al., 2011). In response to acquisition of an activated oncogene, primary human cells can enter a prolif-
eration-arrested senescent state (oncogene-induced senescence [OIS]) that suppresses tumor formation
(Michaloglou et al., 2005; Chen et al., 2005; Braig et al., 2005; Collado et al., 2005; He and Sharpless,
2017). Senescent cells also exhibit an altered secretory program, the so-called Senescence Associated
Secretory Phenotype (SASP) (Kuilman et al., 2008; Acosta et al., 2008; Krtolica et al., 2001) comprised of
pro-inflammatory cytokines and chemokines, which also contributes to tumor suppression by promoting
clearance of senescent cells by the immune system (Lujambio et al., 2013; Xue et al., 2007; Kang et al.,
2011).
Conversely, CpG island methylator phenotype (CIMP) is thought to contribute to bypass of tumor suppres-
sor mechanisms by epigenetic silencing of tumor suppressor genes, such asMLH1 and CDKN2A (Lao and
Grady, 2011). In CRC, BRAFV600E mutation and CIMP are quite tightly linked (Ogino et al., 2009; Weisen-
berger et al., 2006; Inoue et al., 2015; Nagasaka et al., 2004, 2008; Hinoue et al., 2012; Cancer Genome Atlas
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Network, 2012), leading to speculation that BRAFV600E promotes and/or selects for CIMP en route to tu-
mor progression. Because CDKN2A encodes p16, a key effector of cellular senescence (He and Sharpless,
2017), CIMP might be expected to suppress OIS.
DNA methyl transferase 3B (DNMT3B) is a so-called de novo DNA methyl transferase, capable of methyl-
ating CpGs where both CpGs of the palindrome are in the unmethylated state. In normal mouse intestine,
inactivation of Dnmtb does not have a marked phenotype (Elliott et al., 2016; Lin et al., 2006). However,
several studies have suggested that elevated DNMT3B might cooperate with BRAFV600E to drive tumor-
igenesis and that DNMT3B is responsible for methylation of DNA to generate CIMP (Carragher et al., 2010;
Fang et al., 2014; Ibrahim et al., 2011; Nosho et al., 2009). According to onemodel in which the link between
oncogene activation and CIMP can be quite indirect, oncogene-induced senescence and/or other onco-
gene-activated p53 and p16-dependent tumor suppressor mechanisms provide the selective pressure
for DNMT3B and CIMP-mediated silencing of these key tumor suppressor pathways. Consistent with
this model, in a mouse model of BrafV600E-driven colon cancer, escape from senescence and tumor pro-
gression was linked to increased expression of Dnmt3b and methylation and silencing of p16
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Figure 1. DNMT3B Is Frequently Amplified and Overexpressed in CRC
(A) Violin plot showing distribution of DNMT3B expression levels in 207 CRC tumor samples. Mann-Whitney U test;
p value = 5.785e-10.
(B) DNMT3B relative copy number across 207 tumor samples. Lines at y axis 0.2 and 0.2 indicate the threshold for
deletion and amplification, respectively.
(C) Median centered log2 DNMT3B mRNA expression plot from 207 tumor samples (TCGA) annotated with BRAF
mutation status.
(D) The relationship between DNMT3B relative copy number and DNMT3B mRNA expression in 207 tumor samples.
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(Carragher et al., 2010). According to this model, although activated BRAFV600E can increase the selective
pressure that favors CIMP, methylation is not directly caused by BRAFV600E but has an inherent tendency
to encroach on unmethylated CpG islands during aging (Skvortsova et al., 2019; Ushijima and Suzuki, 2019;
Tao et al., 2019). In another model that more directly links oncogenic signaling and CIMP, it has been pro-
posed that BRAFV600E signaling recruits DNMT3B to genes silenced by CIMP via the transcriptional
repressor, MAFG, thereby directly promoting CIMP (Fang et al., 2014, 2016).
However, studies into the relationship between BRAFV600E and DNMT3B to this point are incomplete. For
example, their associations in human TCGA data and functional interactions in mouse models have not, as
far as we are aware, been considered in detail in previous studies. Here we set out to investigate whether
BRAFV600E and DNMT3B cooperate in intestinal tumorigenesis by examination of human tumor data,
in vitromodels of senescence, andmouse models of CRC. The results present a mixed story, but are impor-
tant for the field, and, on balance, lead us to suggest that BRAFV600E mutation and DNMT3B do not
frequently cooperate to promote CIMP and human intestinal cancer.
RESULTS
DNMT3B Is Frequently Amplified and Overexpressed in Human CRC
To begin to probe the putative oncogenic function of DNMT3B in human CRC, we mined human TCGA
data examining levels of DNMT3B expression and gene copy number. First, we confirmed that, at the
mRNA level, DNMT3B is expressed at a higher level in human CRC than normal human colon (Figures
1A and S1A–S1C). We also found that the DNMT3B gene exhibits increased copy number, indicative
of gene amplification, in a substantial proportion of CRC (Figure 1B). Amplification of DNMT3B in human
CRC is also apparent via Database: cbioportal.org (Gao et al., 2013). Moreover, comparing DNMT3B
mRNA expression and gene copy number revealed a correlation between DNMT3B copy number and
mRNA expression (Figures 1C and 1D). These data are consistent with the idea that increased DNMT3B
expression can be oncogenic and suggest that increased expression in human CRC is often a result of
gene amplification.
Ectopic Expression of DNMT3B Antagonizes BRAFV600E-Induced Proliferation Arrest and
SASP
Previous studies suggested that elevated DNMT3B might cooperate with BRAFV600E to drive tumorigen-
esis (Carragher et al., 2010; Fang et al., 2014; Ibrahim et al., 2011; Nosho et al., 2009). To investigate this
possibility of oncogenic cooperation between BRAFV600E and elevated DNMT3B, we tested functional in-
teractions between the two in an in vitro cell culture model. In the absence of a robust normal human
colonic epithelial cell model, we turned to primary human fibroblasts that were previously used to model
molecular events underlying CIMP in CRC (Fang et al., 2014) and more generally have been a paradigm for
investigatingmechanisms of oncogene cooperation in human cells (Hahn et al., 1999, 2002). Primary human
IMR90 fibroblasts were infected with drug-selectable lentiviruses directing expression of BRAFV600E,
DNMT3B, or empty vector as a control. Both proteins were efficiently expressed for up to 10 days post-
infection (Figure 2A). When expressed on its own, activated BRAFV600E induced a marked decrease in
the percent of cells in S phase of the cell cycle, in line with this oncogene’s ability to induce senescence-
associated proliferation arrest in primary cells (Michaloglou et al., 2005; Pawlikowski et al., 2013) (Fig-
ure S2A). The decline in cells in S phase was accompanied by decreased abundance of cell cycle drivers,
cyclin A, and phosphorylated pRB, and, perhaps accounting for decreased phosphorylated pRB through
regulation of p16INK4A (McHugh and Gil, 2018), decreased expression of EZH2 (Figure 2A). Ectopic
expression of DNMT3B increased the proportion of cells in S phase, proportionately more so in cells ectop-
ically expressing BRAFV600E (Figures 2B and S2A). In cells expressing both BRAFV600E and DNMT3B
compared with those expressing BRAFV600E only, this was accompanied by increased cyclin A, EZH2
and phosphorylated pRB, and, at the seven-day time point, a consistent decrease in expression of cell cycle
inhibitor, CDKN1B (p27KIP1) (Figure 2A). Expression of DNMT3B alone had no detectable effect on these
key cell-cycle regulators (Figure 2A). We conclude that elevated DNMT3B antagonizes BRAFV600E-
induced cell-cycle arrest.
To better understand the effect of DNMT3B on BRAFV600E-induced cell-cycle arrest, we infected cells with
empty vector, DNMT3B alone, BRAFV600E alone, or the combination and performed RNA-seq. Principal
component analysis showed that three replicates of each condition expressed distinct transcriptomes (Fig-
ure S2B). Expression of activated BRAFV600E significantly increased and decreased expression of 3403 and
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Figure 2. DNMT3B Suppresses Features of OIS
(A) Kinetic analysis assessing the impact of ectopic DNMT3B on markers of BRAFV600E-induced cell-cycle exit of primary
IMR90 cells, determined by Western blot. MW markers in kDa.
(B) Impact of ectopic DNMT3B on BRAFV600E-induced S-phase exit of primary IMR90 cells, determined by BrdU labeling.
Each group n = 4, from days 3, 5, 7, and 10 post-infection. Middle line = median; box top/bottom = upper and lower
quartiles; whiskers 90th (upper) & 10th (lower) percentile of data. Kruskal-Wallis test, p < 0.05.
(C) Number of significantly differentially expressed genes between indicated pairwise comparisons of primary IMR90 cells
expressing ectopic BRAFV600E and/or DNMT3B and/or empty vectors, determined from RNA-seq FPKM values (Cuffdiff,
FDR corrected p value of <0.05).
(D) Number of significantly up or down genes between indicated pairwise comparisons of primary IMR90 cells expressing
ectopic BRAFV600E and/or DNMT3B and/or empty vectors, determined from RNA-seq FPKM values.
(E) Heatmap of expression of significant changed proliferation-associated genes.
(F) Heatmap of expression of significant changed SASP genes.
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Figure 3. DNMT3B Accelerates Intestinal Cancer
(A) Western blot showing doxycycline-inducible expression of Dnmt3b in small intestine (S) and colon (C) of R26-M2-
rtTA;Col1a1-tetO-Dnmt3b1 and R26-M2-rtTA;WT mice. MW markers in kDa.
(B) Number of small intestine tumors in VilCreErT2;LSL BrafV600E mice with and without ectopic Dnmt3b expression.
Mean with error bars /+ SEM. Mann Whitney test p = 0.98 (ns) n = 5 vs 5.
(C) Representative small intestine tumor fromVilCreErT2;LSL BrafV600E mice, similar with or without Dnmt3b.
(D) Representative immunohistochemistry images for Ki67 in VilCreErT2; LSLBrafV600E mice with and without ectopic
Dnmt3b. Scale bars are 200 mM.
(E) Representative immunohistochemistry images for p21 in VilCreErT2;LSLBrafV600E mice with and without ectopic
Dnmt3b. Scale bars are 200 mM.
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5745 genes, respectively (Figures 2C and 2D). These changes in gene expression include those character-
istic of OIS, including repression of cell cycle genes and activation of inflammatory genes indicative of the
SASP (Figures 2E and 2F). However, co-expression of DNMT3B antagonized a substantial proportion of the
gene expression changes induced by BRAFV600E (Figure 2D) (specifically, 1,055 of genes upregulated by
BRAFV600E and 2,546 of genes downregulated by BRAFV600E). Consistent with the previous cell-cycle an-
alyses (Figures 2A, 2B, and S2A), DNMT3B modestly suppressed BRAFV600E-induced repression of many
cell proliferation genes (Figures 2E, S2C, and S2D). In addition, DNMT3Bmarkedly suppressedmany of the
SASP genes induced by BRAFV600E (Figure 2F). DNMT3B-mediated suppression of BRAFV600E-induced
repression of cell-cycle genes and activation of SASP was also apparent by GSEA analysis (Figure S2E). In
sum, elevated DNMT3B impaired two key tumor suppressive phenotypes induced by BRAFV600E in pri-
mary human cells, cell-cycle arrest and SASP. These data show that combined expression of BRAFV600E
and DNMT3b could cooperate to promote tumorigenesis.
Dnmt3b Enhances Tumorigenesis and Decreases Survival in a BrafV600E-Driven Mouse
Model of Intestinal Cancer
To investigate the tumor promoting potential of combined BrafV600E mutation and elevated Dnmt3b
in vivo, we tested the two in an in vivomouse model of intestinal tumorigenesis. A previous study reported
that mouse intestinal-specific expression of activated Braf under control of a constitutive villin-Cre recapit-
ulates features of the human serrated pathway of intestinal tumorigenesis (Rad et al., 2013). In an effort to
better mimic cancer initiation in human adult tissues, in a modified version of this model, mice expressing
a conditional-activated intestinal-specific BrafV600E oncogene under the control of tamoxifen-inducible
Villin-Cre-ERT2 were crossed to mice expressing conditional Dnmt3b under control of doxycycline induc-
ible rtTA (el Marjou et al., 2004; Linhart et al., 2007; Steine et al., 2011). Transgene expression was induced in
6- to 10-week-old mice, and western blotting confirmed inducible expression of Dnmt3b in the small intes-
tine and colon (Figure 3A). Mice were culled when they showed comparable clinical signs of disease.
Accordingly, at the time the BrafV600E and BrafV600E/Dnmt3b mice were culled, the two groups harbored
a comparable number of small intestinal tumors (Figures 3B and 3C); no overt differences in tumor histol-
ogy were noted between BrafV600E and BrafV600E/Dnmt3b tumors. No colonic tumors were identifiable in
any mice examined. At this time, we did not detect any overt differences between proliferation and senes-
cence markers in BrafV600E/Dnmt3b and BrafV600E mice, in either tumor or histologically normal intestine
(Figures 3D, 3E, and S3A and data not shown). Strikingly, however, combined ectopic Dnmt3b expression
together with activated BrafV600E in the murine intestine resulted in a marked decrease in overall survival
compared with BrafV600E alone (Figure 3F). Median post-survival induction in mice expressing BrafV600E
and endogenous Dnmt3b was 489 days, compared with 289 in mice with ectopic BrafV600E and Dnmt3b.
Mice expressing ectopic Dnmt3b alone did not develop any clinical signs of illness up until 377 days
following induction and were culled at this time. Neither intestinal abnormalities nor tumors were identified
in these mice, consistent with previous reports (Steine et al., 2011; Linhart et al., 2007). These results sug-
gest that elevated Dnmt3b accelerated the accumulation of a lethal burden of BrafV600E-driven intestinal
tumors.
To test whether Dnmt3b is required for BrafV600E-induced intestinal tumorigenesis, we generated mice
harboring a conditionally activated BrafV600E oncogene and conditionally inactivated Dnmt3bfl/fl, both
under control of Villin-Cre-ERT2 (Figure S3B). Similar to the observations with elevated Dnmt3b, inacti-
vation of Dnmt3b did not significantly affect the number of intestinal tumors at the time of terminal dis-
ease (Figure 3G). Again, no differences in tumor histology were noted either. However, inactivation of
Dnmt3b did significantly extend survival of mice harboring BrafV600E (Figure 3H). Consistent with the
previous elevated Dnmt3b model, these results suggest that abundance of Dnmt3b is rate-limiting for
acquisition of a lethal burden of tumors in this BrafV600E-induced intestinal cancer model. Overall,
Figure 3. Continued
(F) Kaplan-Meier curve comparing survival in VilCreErT2; LSLBrafV600E mice with and without intestinal Dnmt3b ectopic
expression. ‘‘DNMT3B only’’ mice (‘‘Col1a1-tetO-Dnmt3b1 +/’’) also shown. Log rank (Mantel-Cox) test, p < 0.0001.
(G) Total small intestine tumor number in VilCreErT2; LSLBrafV600E; Dnmt3bwt/wt and VilCreErT2; LSLBrafV600E;
Dnmt3bfl/fl mice. Mann Whitney test p = 0.42; n = 5 vs 5. Mean with error bars /+ SEM.
(H) Kaplan-Meier curve of survival in VilCreErT2;LSLBrafV600E mice with wild-type or floxed Dnmt3b. Log Rank
(Mantel-Cox) test, p < 0.02.
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Figure 4. Ectopic Expression of DNMT3B Does Not Induce CIMP
(A) Western blot of lysates from human fetal lung fibroblasts (IMR-90) infected with lentivirus directing expression of
BRAFV600E or corresponding empty vector. MW markers in kDa.
(B) Scatterplot of CpG methylation in BRAFV600E-infected fibroblasts compared with proliferating ‘‘vector’’ controls
(top), and replicative senescent (PD88) compared with proliferating controls (PD28) (bottom).
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these data support the notion that the combination of BrafV600E and elevated Dnmt3b can be potently
oncogenic in CRC.
Activated BRAFV600E Repressed Expression of DNMT3b and Failed to Induce a CIMP
Phenotype
According to a previously proposed model, activated BRAFV600E signaling recruits DNMT3B to genes
silenced by CIMP via the transcriptional repressor, MAFG (Fang et al., 2014, 2016). This model was based,
in part, on the ability of BRAFV600E to increase expression of MAFG and decrease expression of CIMP
target gene MLH1 in primary human fibroblasts (Fang et al., 2014). To extend this line of investigation,
we ectopically expressed activated BRAFV600E in primary human fibroblasts and assessed its impact on
DNMT3B and CIMP. As shown previously (Michaloglou et al., 2005), ectopic expression of BRAFV600E
induced proliferation arrest and upregulation of markers of senescence (Figures 2A and 4A). However, sur-
prisingly, activated BRAFV600E triggered downregulation of DNMT3B expression (Figure 4A). Next, we set
out to ask whether oncogenic BRAFV600E is able to induce methylation changes characteristic of CIMP.
Primary human fibroblasts were again infected with a lentivirus directing expression of BRAFV600E. Seven
days after infection, the cells were harvested, DNA prepared, and subject to WGBS to map the DNAmeth-
ylome. Principal Component Analysis poorly separated the control and BRAFV600E-expressing cells
(Figure S4A). Consistent with this, although we reported previously that replicative senescent (RS) cells un-
dergo a marked global hypomethylation (Cruickshanks et al., 2013), BRAFV600E-expressing cells showed
only a very small overall gain in methylation (Figure S4B). A scatterplot of CpGmethylation in control versus
BRAFV600E-expressing cells also revealed no substantial differences, in contrast to a comparison of
proliferating and replicative senescent fibroblasts, which revealed marked hypomethylation in the latter
(Figure 4B) (Cruickshanks et al., 2013). The relative similarity of vector and BRAFV600E cells, compared
with proliferating versus replicative senescent, was underscored by whole chromosome difference plot
(Figure S4B). This revealed the marked hypomethylation of lamin-associated domains (LADs) in replicative
senescent cells reported previously (Cruickshanks et al., 2013), but this was absent from BRAFV600E cells
(Figure S4B). Indeed, although many significantly differentially methylated individual CpGs and regions
(DMRs) were detected between proliferating and RS cells, very few were detected between control and
BRAFV600E-expressing cells (Figure S4C). Although increasing the window size of candidate DMRs
decreased the number of DMRs detected in replicative senescent cells due tomerging of small DMRs, vary-
ing the size of candidate DMRs did not majorly affect the number of DMRs detected in BRAFV600E cells
(Figure S4C). Most relevant to a candidate CIMP-like phenotype, BRAFV600E-expressing cells did not
gain methylation at CpG islands whose methylation is diagnostic of CIMP, including MLH1, CACNA1G,
CDKN2A, CRABP1, and NEUROG1; this is in contrast to replicative senescent cells (Figure 4C) (Cruick-
shanks et al., 2013). Taken together, these results do not support a role for BRAFV600E in direct induction
of CIMP via DNMT3B, at least in fibroblasts.
BRAFV600E Mutation Is Neither Necessary nor Sufficient for CIMP, and BRAFV600E
Mutations and CIMP Are Both Linked to a Low Expression of DNMT3B
In light of these functional data, we turned again to human TCGA data to shed more light on the potential
interactions between BRAFV600E and DNMT3B in human CRC. First, we clustered patient samples based
on methylation values of all probes at CpG islands showing significant variance across the human TCGA
CRC datasets. As expected, this separated out human CRC into at least three groups, one of relatively
high methylation at CpG islands, CIMP high (CIMP-H), and CIMP low (CIMP-L) and non-CIMP (Hinoue
et al., 2012; Cancer Genome Atlas Network, 2012) (Figure 5A). As expected, and as reported previously (Hi-
noue et al., 2012; Cancer Genome Atlas Network, 2012; Weisenberger et al., 2006; Samowitz et al., 2005a),
CIMP-H tumors associated with BRAFV600Emutation (Figure 5A) (2.16-fold enrichment, p < 0.001). Some-
what surprisingly, however, CIMP-H tumors were anti-correlated with DNMT3B copy number amplification
(Figure 5A) (0.21-fold enrichment, p < 0.001). The same relationship was apparent when we analyzed only
samples with microsatellite instability (MSI+), known to be enriched in CIMP (Guinney et al., 2015) (Fig-
ure S5A). To examine more closely the relationship between CIMP and DNMT3B amplification, we rank-or-
dered all human CRC samples by the degree of DNMT3B amplification (which correlates with expression
Figure 4. Continued
(C) Smoothened methylation plots of CIMP panel genes in vector and BRAFV600E-expressing cells. Red and blue lines
indicate the smoothened average percentage methylation at corresponding CpGs. Individual CpGs are indicated by
black ‘‘ticks’’ along the x axis.
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Figure 5. Human BRAFV600E/CIMP Tumors Express Low Levels of DNMT3B
(A) Clustering of TCGA human CRC based on Illumina 450K DNAmethylation array data (all CpGs showing variation >0.2
StdDev). BRAF mutation and DNMT3B amplification status are shown below (red = mutated/amplified).
(B) CpG probes (y axis of the heatmap) clustered based on increasing DNMT3B copy number (x axis of the heatmap).
(C) Relationship between DNMT3B copy number and methylation of CIMP biomarker genes (CACNA1G, RUNX3, IGF2,
MLH1, NEUROG1, CRABP1, CDKN2A). Red line marks the boundary between non-amplified and amplified DNMT3B.
Each black dot indicates the mean methylation score in the indicated probes in one patient sample. Y axis—mean
methylation, x axis—relative copy number.
(D) Boxplot of DNMT3B FPKM mRNA expression in human colorectal carcinoma TCGA patients subdivided by CIMP
status. Mann Whitney test, p = 0.001.
(E) Violin plot showing distribution of DNMT3B expression levels in 207 CRC tumor samples, separated according to
BRAF WT or BRAFV600E mutant. p value = 0.0001.
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(Figures 1C and 1D)) and compared with CIMP. Amplification of DNMT3B was not associated with CIMP
and, indeed, the tumors with the most overt CIMP appeared to associate with relatively low DNMT3B
copy number (Figure 5B). Next, we directly compared CIMP score with DNMT3B amplification or expres-
sion. This confirmed an inverse relationship between CIMP and both DNMT3B amplification and expres-
sion (Figures 5C, 5D, and S5A). Finally, we directly compared DNMT3B expression and BRAFV600E muta-
tion. This showed that DNMT3B expression is higher in those tumors with wild-type BRAF (Figures 5E, S5C,
and S5D). In sum, this analysis of human TCGA confirms the strong association between BRAFmutation and
CIMP-H but does not support a marked association between amplification and increased expression of
DNMT3B and either BRAF mutation or CIMP-H and so challenges the idea that elevated DNMT3B contrib-
utes to BRAFV600E-induced tumorigenesis and associated CIMP in humans.
DISCUSSION
Approximately 10% of human colorectal cancers harbor a BRAFV600E mutation, which has been demon-
strated to act as a founder mutation for an alternative serrated pathway of colorectal carcinogenesis (Can-
cer Genome Atlas Network, 2012; Fransen et al., 2004; Vaughn et al., 2011; Giannakis et al., 2016; Carragher
et al., 2010; Rad et al., 2013). However, on its own, both in vitro and in vivo, activated oncogenic BRAFV600E
induces OIS, an established tumour-suppressive mechanism (Michaloglou et al., 2005; Carragher et al.,
2010; Rad et al., 2013; Dankort et al., 2007). Consistent with a potent BRAFV600E-induced tumor suppres-
sor mechanism in humans, activating BRAFV600E mutations are detectable in 62%–70% of hyperplastic
colonic polyps: lesions traditionally considered to harbor no oncogenic potential (Yang et al., 2004; Mesteri
et al., 2014). Furthermore, the existence of an OIS barrier in human serrated pathway carcinogenesis is sup-
ported by the published in situ data (Kriegl et al., 2011).
It is clear, therefore, that additional genetic and/or epigenetic events are required to promote neoplastic
transformation in the serrated pathway, which if untreated (e.g. by endoscopic polypectomy) eventually
culminates in the development of invasive carcinoma. CIMP is thought to promote tumorigenesis by
bypass of tumour-suppressor mechanisms, such as silencing of CDKN2A/INK4A (Kriegl et al., 2011; Carra-
gher et al., 2010). It has been recognized for some time that there is an extremely close relationship be-
tween BRAFV600E mutations and CIMP-H in human colorectal cancer (Ogino et al., 2009; Weisenberger
et al., 2006; Inoue et al., 2015; Nagasaka et al., 2004, 2008; Hinoue et al., 2012; Cancer Genome Atlas
Network, 2012). Although this association was initially correlative, it has recently been proposed that
BRAFV600E can directly induce CIMP through the de novo methyltransferase, DNMT3B (Fang et al.,
2014, 2016). Separately, elevated DNMT3B expression has previously been linked to the development of
CIMP in both murine and human colorectal neoplasia (Carragher et al., 2010; Ibrahim et al., 2011; Nosho
et al., 2009; Steine et al., 2011). Furthermore, DNMT3B has been demonstrated to have an oncogenic func-
tion in murine colon cancer (Lin et al., 2006; Linhart et al., 2007). Thus, the emerging dogma is of a model in
which neoplastic transformation in BRAFV600E-mutant colorectal serrated lesions may be contributed to
by the ability of this oncogene to induce a CpG island methylator phenotype, mediated by DNMT3B.
There are, however, several obvious paradoxes. Firstly, only a minority of colorectal lesions harboring an
activating BRAFV600E mutation eventually progress to invasive carcinoma (Yang et al., 2004; Mesteri
et al., 2014). Secondly, CIMP develops gradually with serrated pathway progression (Inoue et al., 2015).
Thirdly, as many as 40% of CIMP-H tumors do not harbor an activating BRAFV600E mutation. Finally,
approximately 10% of patients with an activating BRAFV600E mutation are CIMP-L or CIMP-negative
(Ogino et al., 2009). Thus, a simple, linear model by which BRAFV600E directly induces CIMP cannot be fully
reconciled with the disease biology. We therefore set out to comprehensively examine the relationships
between an activated BRAFV600E oncogene, DNMT3B, and CIMP in colorectal cancer by multiple
approaches.
Because activated BRAFV600E is a potent inducer of OIS (Michaloglou et al., 2005; Carragher et al., 2010;
Rad et al., 2013; Dankort et al., 2007), we initially set out to test the idea that elevated DNMT3B can bypass
BRAFV600E-induced OIS. Indeed, ectopic expression of DNMT3B together with BRAFV600E partially sup-
pressed two phenotypes characteristic of BRAFV600E-induced OIS, namely proliferation arrest and, most
notably, SASP. Extending these results in vivo, conditional inducible and knockout mouse models showed
that expression of Dnmt3b is rate-limiting for accumulation of a lethal burden of BrafV600E-driven tumors
in mouse intestinal epithelium. The molecular mechanisms underlying these phenotypes remain to be es-
tablished. Conceivably, suppression of SASP gene expression by DNMT3B could depend on suppression
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of BRAFV600E signaling, de novo methylation of SASP genes, or another mechanism. Regardless of the
specific mechanism, these in vitro and in vivo lines of evidence support an oncogenic function for DNMT3B
in cooperation with BRAFV600E.
However, our other analyses do not support a role for DNMT3B cooperating with activated BRAFV600E via
its induction of CIMP. Since activated BRAFV600E has been proposed to directly potentiate DNMT3B-
mediated CIMP and silencing of tumor suppressor genes (Fang et al., 2014, 2016), we wondered whether
BRAFV600E-induced OIS might simultaneously sow the seeds of its own destruction, in the form of
DNMT3B-mediated CIMP. However, in contrast to replicative senescent cells, in OIS BRAFV600E efficiently
repressed expression of DNMT3B, and we observed very few BRAFV600E-induced DNA methylation
changes. Finally, a closer examination of human TCGA data suggests that BRAFV600E and DNMT3B are
unlikely to cooperate in tumorigenesis, and DNMT3B is unlikely to mediate CIMP. Analysis of data acces-
sible through cBioportal, including TCGA and the largest study of 1,134 samples (Yaeger et al., 2018; Gao
et al., 2013), also indicates that BRAFV600Emutation andDNMT3B amplification tend to bemutually exclu-
sive. Taken together, these in vitro and in silico studies suggest that in BRAFV600E-driven CRC, elevated
DNMT3B is likely not the cause of CIMP, and BRAFV600E and DNMT3B are unlikely to cooperate in pro-
gression of this disease. In summary, the data presented herein challenge the current model of the relation-
ships between BRAF, DNMT3B, and CIMP in human colorectal cancer, whereby DNMT3B contributes to
CIMP in association with BRAFV600E mutation and, in the most extreme form of the model, that mutant-
BRAFV600E drives CIMP via DNMT3B. By multiple approaches, in vitro and by in silico analysis of TCGA,
we have demonstrated that BRAFV600E mutation is associated with and can cause repression of DNMT3B.
Furthermore, although DNMT3B overexpression and somatic copy number amplification are common fea-
tures of human colorectal cancer, they are inversely correlated with CIMP. In functional in vitro studies, we
obtained no evidence that DNMT3B is a driver of CIMP. Thus, although BRAFV600E andDNMT3B both har-
bor oncogenic potential, they do not appear to cooperate to induce CIMP and do not appear to cooperate
frequently in human colorectal cancer by any mechanism.
Limitations of the Study
Of course, there are limitations to these conclusions drawn in part from ‘‘negative data’’ that we have been
unable to address over the time frame of this study. First, although BRAFV600E does not induce detectable
methylation changes characteristic of CIMP in a bulk population of cells, we cannot exclude the possibility
that it does so in a very small subset of cells that is then prone to senescence escape, clonal outgrowth, and
tumorigenesis. Even so, comparison of ourWGBS data reported here forOIS with our previous studies in RS
suggest that CIMP is more likely to arise in RS cells linked to other cumulative molecular stresses, e.g. telo-
mere shortening, than inOIS cells (Cruickshanks et al., 2013). Second, our analysis of humanTCGAdata does
not preclude an association between DNMT3B expression and BRAFV600E at very early stages of disease,
prior to detection and inclusion of tumors in the TCGA study. Although these limitations may go some way
toward reconciling our conclusions with those of previous studies, it is important to note that prior functional
studies most directly linking DNMT3B to CIMP have been performed in established colon cancer cell lines
in vitro (Fang et al., 2014). Despite these limitations to our study, we feel that, on balance, the weight of ev-
idence does not support a role for DNMT3B and BRAFV600E cooperating in intestinal cancer.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
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Figure S1 (Related to Figure 1). A Boxplot of relative DNMT3B mRNA expression in 22 
human colorectal adenocarcinoma samples (TCGA) and matched non-tumor (surrounding 
normal) samples. B Density plot of DNMT3B expression distribution in 207 human colorectal 
adenocarcinoma samples (TCGA) and 43 available non-tumour samples. C A histogram of 
DNMT3B mRNA expression in 22 tumor and matched non-tumor (surrounding normal) 
samples. 
 
Figure S2 (Related to Figure 2). DNMT3B suppresses features of OIS. A Kinetic analysis 
assessing the impact of ectopic DNMT3B on BRAFV600E-induced S-phase exit of primary 
IMR90 cells, determined by BrdU labelling. B PCA analysis of RNA-seq from Figure 2C-F. C 
RNA-seq reads at CCNA2 gene in BRAFV600E (bottom) and BRAFV600E+DNMT3B (top) 
samples. D RNA-seq reads at CKS2 gene in BRAFV600E (bottom) and 
BRAFV600E+DNMT3B (top) samples. E GSEA analysis of RNA-seq data showing 
downregulation of cytokine activity and increased mitotic nuclear division gene sets by 
DNMT3B.  
 
Figure S3 (Related to Figure 3). DNMT3B accelerates intestinal cancer. A Representative 
immunohistochemistry images for cyclin D1 and b-catenin in VilCreErT2;LSLBRAFV600E mice 
with and without ectopic DNMT3B. Scale bars are 200µM. B Western blot of DNMT3B in 
VilCreErT2;LSLBRAFV600E mice with wild-type or floxed DNMT3B. MW markers in kDa.  
 
Figure S4 (Related to Figure 4). Ectopic expression of DBNMT3B does not induce CIMP. 
A  Principal component analysis was performed on both biological replicates of 
BRAFV600E (BRAF) and proliferating (vector) controls. B  Fractional methylation of a 
representative region of chromosome 10 in vector control cells, BRAFV600E-infected cells 
(BRAF), proliferating cells and replicative senescent cells. Bottom two tracks show the 
subtraction of BRAFV600E-control and replicative senescent – proliferating cells. C Number of 
hypo and hypermethylated DMRs in BRAFV600E-infected cells (left) and replicative senescent 
cells (right).  
 
Figure S5 (Related to Figure 5). Human BRAFV600E/CIMP tumors express low levels of 
DNMT3B. A Clustering of TCGA human MSI+ (MSI-L and MSI-H) CRC based on Illumina 
450K DNA methylation array data (all CpGs showing variation > 0.2 StdDev). BRAF mutation 
and DNMT3B amplification status are shown below (red = mutated/amplified). B Relationship 
between DNMT3B FPKM expression and methylation of CIMP biomarker genes (CACNA1G, 
RUNX3, IGF2, MLH1, NEUROG1, CRABP1, CDKN2A). Each black dot indicates the mean 
methylation score in the indicated probes in one patient sample. Y-axis – mean methylation, x-
axis – relative FPKM expression. C  Boxplot of log2 DNMT3B FPKM mRNA expression and 
BRAFV600E  mutation status from 207 human colorectal adenocarcinoma samples (TCGA). 
Mann Whitney test p = 0.0002. D Median centred log2  DNMT3B mRNA expression plot 
annotated by DNMT3B copy number status. 
 
Materials and Methods 
Cell culture 
Human female fetal lung fibroblasts (IMR-90) were grown in DMEM supplemented with 10% 
FBS, 2mM L-glutamine, 10units/mL Penicillin G and 10µg/ml streptomycin. Cells were cultured 
in 10cm plates in a humidified atmosphere with 3% O2 and 5% CO2. Passaging of cells was 
performed at 70-80% confluency. Culture media were aspirated, and the cells lavaged twice with 
sterile phosphate-buffered saline to remove remaining traces of culture media. Trypsinisation 
was then performed with 1mL of 1% trypsin in phosphate-buffered EDTA solution for 3 minutes 
at 37°C. With cell detachment confirmed by visual inspection with a microscope, the trypsin 
solution was neutralised by the addition of fresh culture media (supplemented with FBS) to the 
plate. Cells were then resuspended in culture media, passaged to fresh plates, and returned to the 
incubator.  
 
Lentivirus infections 
Cells were infected with lentiviruses directing expression of DNMT3B1 and/or BRAFV600E. 
Viruses were made from pLenti6-puro-DNMT3B1 (or pLenti6-puro as control) and/or HIV-CS-
CG-blast-BRAFV600E (or HIV-CS-CG-blast as control). HIV-CS-CG-blast plasmids were a gift 
of Dr. Daniel Peeper (NKI).  
 12x106 HEK-293T cells were seeded in 25 mL of culture medium to TC175 flasks 20 
hours prior to transfection. Cells were approximately 70% confluent for transfection. 
Immediately prior to transfection, 13mL of culture medium was aspirated from flasks, and the 
cells returned to the incubator. Lipofectamine 2000 was selected as a transfection agent for all 
lentivirus production. 120µL of transfection agent were added dropwise to 1.5mL of sterile 
DMEM in a 15mL centrifuge tube, gently agitated and incubated for five minutes at room 
temperature. Concurrently, packaging plasmids (5µg plpVSVG and 8µg psPAX2) were 
combined with 20µg of vector genome in 1.5mL of sterile DMEM in a separate 15mL centrifuge 
tube. Thereafter the DNA and transfection reagent solutions were combined, gently agitated and 
incubated for 20 minutes at room temperature. The transfection solution was then added to the 
prepared HEK-293T flasks to yield a total final transfection volume of 15mL. Following 
transfection, HEK-293T cells were returned to the incubator for six hours, following which the 
transfection solution was aspirated, and a fresh 15mL of culture medium added to the flask. For 
all transfections, a separate green fluorescent protein (GFP) control transfection was performed 
in parallel to confirm transfection efficiency. 
After a period of twenty hours following transfection, GFP controls were examined to 
confirm transfection efficiency. Lentiviral supernatant was then aspirated from transfected HEK-
293T cells, reserved and stored at 4°C. A further 15mL of culture medium was added to the 
HEK-293T cells and returned to the incubator for a further twenty hours. The second lentiviral 
supernatant fraction was then combined with the first, centrifuged at 3000RPM in a table-top 
centrifuge, and filtered through a 0.45µM low-protein binding PVDF filter prior to concentration. 
Filtered viral supernatants were transferred to sterile 38.5mL polypropylene centrifuge tubes 
(Beckman 326823) and weights equalised by the addition of sterile PBS. Ultracentrifugation was 
performed at 47,000 x g in an SW-28 Beckman- Coulter ultracentrifuge for two hours at 10°C. 
Following centrifugation, the supernatant was discarded by gentle inversion, and the viral pellet 
resuspended in 100µL of sterile PBS overnight at 4°C, prior to being aliquoted and stored at -
80°C. 
The multiplicity of infection (MOI) for lentiviral preparations was calculated empirically 
by seeding cells to a 6-well plate twenty-four hours prior to transduction. Culture medium was 
then aspirated from each well, replaced with 1mL of fresh culture medium supplemented with 
polybrene at a final concentration of 8µg/mL, and the cells returned to the incubator for four 
hours prior to transduction. Concentrated lentivirus was then added to each well at 0, 1, 2, 4, 8 
and 16 µL/mL, and returned to the incubator for sixteen hours. Following transduction, the 
infection medium was removed from each well, and replenished with 2mL of fresh culture 
medium supplemented with the appropriate drug selection as determined by the construct design. 
The minimum volume of lentiviral construct required to yield 100% cell survival following drug-
selection was then employed for all subsequent experiments. All experiments involving 
lentivirus were performed in their entirety under drug selection. 
 
Cell cycle analysis by flow cytometry 
Cell cycle analysis by fluorescence-activated cell sorting (FACS) was performed by combined 5-
bromo-2’-deoxyuridine (BrdU) and propidium iodide (PI) staining. Cells were incubated with 
BrdU at a final concentration of 25µM for 4-24 hours, after which the culture medium was 
aspirated, the cells washed in PBS and trypsinised before being resuspended in culture medium. 
Following resuspension, cells were pelleted, washed in PBS and pelleted. Cell pellets were 
resuspended in 200µL of PBS at 4°C, and fixation achieved by the addition of 2mL of ice-cold 
ethanol prior to gentle vortexing, and storage at 4°C for a minimum of 12 hours prior to further 
analysis. Following fixation, cells were pelleted and resuspended in 1mL of PBS before the 
addition of 1mL of 4N HCl. Cells were then incubated for 15 minutes at room temperature, 
pelleted and the supernatant aspirated. Cells were then resuspended in 1mL of PBS, pelleted and 
resuspended in 1mL of PBT. The cells were then pelleted, before being resuspended in 200µL of 
anti-BrdU antibody diluted 1:40 in PBT. Cells were incubated with primary antibody for one 
hour at room temperature, following which they were pelleted, washed with 1mL PBT and then 
pelleted before being resuspended in 200µL of Alexa-Fluor® 488 goat anti-mouse antibody, 
diluted 1:40 in PBT. Cells were incubated in the dark with secondary antibody at room 
temperature for one hour, following which they were pelleted, and resuspended in 1mL of PBS 
containing propidium iodide at a final concentration of 10µg/mL and RNase A at a final 
concentration of 250µg/mL. FACS analysis was performed using the FACSCalibur analyser, and 
subsequent analysis performed using FlowJo software. 
 
Western blotting 
Protein lysates were prepared in 1x sample buffer (62.5mM Tris-HCl pH6.8, 2% SDS, 10% 
glycerol, 0.1M DTT, 0.01% bromophenol blue). Media was aspirated from tissue culture plates, 
and the cells washed in 10mL of sterile PBS. The PBS was then aspirated, and the cells scraped 
into boiled 1x sample buffer using a plastic scraper and transferred to an Eppendorf tube. The 
contents were vortexed vigorously, aspirated through an 18-gauge needle, and boiled for five 
minutes at 100 °C. Lysates were then centrifuged for 5 minutes in a bench-top microcentrifuge at 
12,000 x g, and flash-frozen in a dry-ice ethanol bath. Protein lysates were stored at -80 °C. The 
protein concentration of lysates in 1 x sample buffer was determined using the Qubit® protein 
assay kit. Pre-diluted BSA standards provided with the kit were used to calibrate the fluorometer 
prior to use, with the addition of 1µL of 1x sample buffer to each of the three protein standards. 
Quantification was undertaken in triplicate for all samples, and a mean protein concentration 
calculated. Electrophoresis of proteins was undertaken using pre-cast SDS-PAGE gradient gels. 
Protein lysates were boiled, and 25µg of total protein loaded per well. Sample volumes were 
equalised using 1x sample buffer. Electrophoresis was undertaken using the Bio Rad Mini-
PROTEAN® Tetra cell system. Loaded gels were assembled in a Mini-PROTEAN® Tetra cell, 
which was filled with 1x SDS-PAGE running buffer (25mM Tris, 192mM glycine, 0.1% SDS, 
pH 8.3), and protein separation achieved by application of a constant current of 200 V. The total 
electrophoresis time was varied depending on the molecular weight of the peptide of interest. 
Following electrophoresis, proteins were immobilised to polyvinylidene fluoride (PVDF). Prior 
to transfer, membranes were soaked in methanol for 30s with gentle agitation, rinsed with dH2O, 
and placed in cold 1 x blotting buffer (25mM Tris pH 8.3, 192 mM glycine, 0.01% SDS, 20% 
methanol). A transfer cassette was assembled, incorporating the gradient gel and PVDF 
membrane, and placed in a Mini Trans-Blot® tank containing 1x blotting buffer. Protein transfer 
was achieved by application of a constant current of 100V, 350mA for 1 hour. Antibodies used : 
β-actin, Sigma A1978, WB 1:200,000. BRAF, Santa Cruz SC5284, WB 1:200. Cyclin A, Santa 
Cruz SC751, WB 1:500. DNMT3B, Imgenex IMG184A, WB (mouse) 1:1000 and Santa Cruz 
SC10236, WB (human) 1:500. EZH2, Cell Signalling 5246, WB 1:1000. GAPDH, Cell 
Signalling 14C10, WB 1:2000. p16INK4A, BD Biosciences BD51-1352GR, WB 1:1000. 
p27KIP1, Cell Signalling 2552s, WB 1:1000. ppRb (Ser807/811), Cell Signalling 9308s, WB 
1:1000. Total Rb, Cell Signalling 9309s, WB 1:1000.  
 
Immunohistochemistry 
Immunohistochemistry was performed by the histology service at the Beatson Institute for 
Cancer Research, Glasgow. Following embedding in paraffin, 4µm sections were cut using a 
microtome. Sections were first dewaxed by immersion in xylene for ten minutes, followed by 
rehydration through serially graded ethanol solutions. Tissues were then washed in deionised 
water for 5 minutes prior to antigen retrieval. Antigen retrieval was achieved by immersion of 
sections in boiled 1x pH6 sodium citrate antigen retrieval buffer for 25 minutes, and sections 
then allowed to cool for 30 minutes, prior to a single wash in Tris-buffered Tween. Endogenous 
peroxidases were then quenched by immersion in a solution of 2% (v/v) hydrogen peroxide in 
methanol for 15 minutes. Following quenching of endogenous peroxidases, samples were 
washed with Tris-buffered Tween. Samples were then blocked by immersion in Tris-buffered 
Tween 1% BSA for 30 minutes. Following blocking, sections were incubated at room 
temperature for 30 minutes with primary antibody prior to 2 washes in Tris-buffered Tween. 
Samples were then incubated with an appropriate HRP-linked secondary antibody for a further 
30 minutes at room temperature prior to a further 2 washes in Tris-buffered Tween. Samples 
were then developed with 3,3’-diaminobenzidine tetrahydrochloride for 10 minutes, washed in 
deionised water for 1 minute, and counterstained for 7 minutes with Haematoxylin Z. Sections 
were then “blued” by submersion for 1 minute in Scott’s water, washed for a further 1 minute in 
deionised water then dehydrated through serially graded alcohols prior to mounting and coverslip 
application.  Antibodies used : β-catenin, BD Biosciences 610154, IHC 1:1200.  Cyclin D1, 
Dako M3642, IHC 1:50. DNMT3B, Imgenex IMG184A, IHC 1:300. Ki67, Thermo Fisher 
RM9106, IHC 1:200. γH2AX, Cell Signalling 9718, IHC 1:50. IL1α R&D Systems AF400, IHC 
1:100. p21WAF, CNiO Institute T3413, IHC 1:4. Sox9, Millipore AB5535, IHC 1:700 
 
Whole genome bisulfite sequencing 
Whole genome bisulfite sequencing was performed by the Beijing Genomics Institute (BGI, 
Shenzhen, China). Following DNA quantification and assessment by agarose electrophoresis, 
genomic DNA was sent for bisulfite sequencing. Briefly, DNA was fragmented by sonication to 
a mean size of approximately 100-300bp, followed by “endblunting”, the addition of dA to the 
3’-end and adapter ligation (the latter allows assessment of the efficiency of bisulfite 
conversion). Bisulfite-conversion was then performed using the Zymo EZ DNA methylation-
Gold kit, which converts unmethylated cytosines to uracils. Bisulfite-treated DNA was then 
subjected to 90bp paired-end sequencing using an Illumina HiSeq-4000 machine. The WGBS 
analysis pipeline has been described previously, and is summarised below (Cruickshanks et al., 
2013). The quality of sequenced reads was first tested using FastQC (version 0.10.0). Thereafter, 
adapters and low-quality sequence tails were excluded using trim-galore (version 0.3.0). 
Alignment of sequence reads to UCSC (hg19) genome was performed using Bismark (version 
0.10.1) based on the Bowtie2 aligner (version 2.1.0) (Krueger and Andrews, 2011). The 
methylation status of each aligned sequence tag was then inferred by comparison to the 
unconverted reference genome. Potential duplicate reads (defined as those reads for which both 
ends of a given fragment align to the same genomic position on the same strand) were then 
removed to control for PCR bias. Furthermore, the exclusion of reads with >3 methylated 
cytosines in a non-CpG context controlled for incomplete bisulfite-conversion. Methylated 
cytosines were then identified by aggregation of processed reads on a per CpG basis, followed by 
the collapsing of CpG dyads into a single score for the cytosine on the forward strand. 
Differentially-methylated CpGs were then identified using a two-tailed Fisher’s exact test. Only 
those CpGs with ≥10 reads within each condition tested were considered for statistical analysis. 
False-positives were controlled at a rate of 5% by means of FDR-correction of p-values using the 
Benjimini-Hochberg FDR function. Global percentage methylation was determined by division 
of the total number of methylated counts by the total number of methylated and unmethylated 
counts in the entire data set, followed by multiplication by 100 for each biological condition. 
Differentially-methylated regions (DMRs) were identified using 500bp sliding-windows. At each 
window, DMR significance was determined using Fisher’s exact test, together with a χ2 test of 
heterogeneity between biological replicates for each condition tested. Multi-sample correction 
was performed using the Benjimini-Hochberg FDR function, and DMRs defined as those 
windows with an FDR-corrected p-value < 0.05 and nonsignificant heterogeneity between 
biological replicates (χ2 test p >0.05). Percentage methylation at any particular DMR was then 
calculated by division of the total number of methylated cytosines by the total number of 
methylated and unmethylated cytosines, multiplied by 100. Genomic feature overlaps were 
calculated on a per-base pair basis between two data sets, and the genomic average expected 
overlap calculated using a permutation test. For composite methylation profiling, the midpoints 
of a series of regions of interest were taken and used as a base. The area around the midpoint of 
each feature was then split into 100bp windows spanning 2.5kb upstream and downstream of this 
central position. The average methylation proportion was then calculated for each window for 
every genomic feature. A global mean was then taken for each window across all features to 
aggregate a composite of the mean methylation per window across all probed genomic features. 
Smoothened methylation plots were generated using the BSmooth algorithm from the bsseq 
package. Methylation levels were kernel-smoothed, and plotted against a range of DMR and 
annotated features in bed format (Hansen et al., 2012). 
 
RNA-seq 
RNA was extracted from adherent cells using the RNeasy Mini Kit according to the 
manufacturer’s protocol. In summary, cell pellets were lysed on ice into buffer RLT 
supplemented with β-mercaptoethanol. Cell lysates were then homogenised by centrifugation in 
QiaShredder columns. RNA isolation was then performed using RNeasy mini kit columns, with 
residual DNA removed by on-column treatment with DNaseI. Following wash steps, RNA was 
eluted into RNase-free distilled water, and stored at -80°C prior to subsequent analysis. Prior to 
sequencing, RNA quantification was performed using the Qubit RNA HS assay kit, and 
qualitative assessment performed using the Agilent RNA ScreenTape assay according to the 
manufacturer’s instructions. RNA-sequencing was performed in the sequencing facility at the 
Beatson Institute for Cancer Research, Glasgow. RNA was prepared for sequencing using the 
TruSeq RNA sample preparation kit. RNA is first purified, fragmented and reverse transcribed to 
produce cDNA. Following the removal of any remaining RNA, single stranded cDNA is 
converted to double stranded cDNA. Blunt-end DNA fragments are then generated. The 
subsequent addition of an “A” base to blunt ends prepares them for ligation to the sequencing 
adapters, which possess a “T” base overhang at the 3’ end, thus providing a complementary 
overhang for adapter ligation. Adapters possess sequencing primer hybridisation sites for single, 
paired-end and multiplex reads. PCR is then employed to selectively enrich for those DNA 
fragments in possession of an adapter molecule on both ends (12 cycles only to prevent skewed 
representation in the library) and then libraries validated using the Agilent DNA 1000 kit. 
Libraries were then sequenced using the Illumina GAIIX sequencer at the Beatson Institute for 
Cancer Research, Glasgow. Paired-end reads were aligned to the human genome (hg19) using a 
splicing-aware aligner (TopHat2) (Kim et al., 2013). Only unique reads were retained. Reference 
splice junctions were provided by a reference transcriptome (Ensembl build 73) and novel 
splicing junctions defined by the detection of reads that spanned exons not in the reference 
annotation. True read abundance at each transcript isoform was assessed using HTSeq (Python) 
before determination of differential expression using CuffDiff, from which differential 
expression and splicing can be derived (Trapnell et al., 2013). Significance was determined using 
an FDR corrected p-value of <0.05. Heatmaps were created in R using the ggplots package. 
 
TCGA data analysis 
All tiers of TCGA data, including Illumina Methylation arrays, RNA-seq, copy-number analysis, 
microsatellite instability (MSI) and mutational (signatures and processed MAF variant files) data 
was downloaded from the legacy TCGA data access portal (now at 
https://portal.gdc.cancer.gov/). We processed the data to ensure that all participants featured in 
subsequent analyses had all aforementioned tiers of data available by merging sample identifiers; 
leaving a sample size of 207 participants.   
 To classify CIMP positive patients, we reduced our methylation matrix by including only 
high variance probes (s >= 0.2) and those that featured in CpG islands.  We then clustered the 
remaining probes initially using the “fastcluster” R package and then using RPMM, before 
classifying participants as CIMP-H, CIMP-L or non CIMP by cutting the cluster dendrogram to 
select those appropriate samples.  Successive copy-number and mutational heatmaps utilized the 
initial CIMP clustering.    
 Focal copy-number amplification or deletion events were classified where the 
segmentation mean [log2()-1] of copy-number surpassed 0.2 or -0.2 respectively, with regression 
analyses performed using the “lm” function from R-Core.  MSI status was called as per TCGA 
data standards (and as performed by the TCGA consortium): microsatellite-stable (MSS), low 
level MSI (MSI-L) if less than 40% of markers were altered, and high level MSI (MSI-H) if 
more than 40% of the markers were altered (per 
http://bioinformaticsfmrp.github.io/TCGAbiolinks/clinical.html#microsatellite_data).  
 
In vivo work 
All experiments were carried out in accordance with the requirements of the UK Home Office 
guidelines under the auspices of Personal License I6C161323, and Project Licence to PDA 
70/8354. Across all experiments, approximately equal numbers of male and female mice were 
used (46 male, 50 female). Mice were typically 8-12 weeks old at time of transgene induction. 
No effects of sex were observed on the results. Routine husbandry of all colonies, including 
nutrition, hydration, setting up of matings, weaning and ear-notching for genotyping was 
undertaken by Biological Services technicians at the Beatson Institute for Cancer Research. Mice 
were fed a standard diet with water ad libitum. The following transgenic alleles were used in this 
study: Tg(Vil-cre/ERT2)23Syr VilCreErT2, Owen Sansom Laboratory (JAX 020282). 
Braftm1Cpri LSLBRAFV600E, Catrin Pritchard Laboratory. B6;129S4-DNMT3Btm1Jae/Mmnc 
(Dnmt3bfl/fl), MMRRC. B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae/J R26-M2-rtTA, Jackson 
Laboratory. B6.Cg-Col1a1tm9(tet0-DNMT3b_i1)Jae/J Col1a1-tetO-DNMT3B1, Jackson 
Laboratory. Routine genotyping was undertaken at weaning (6 weeks age). Ear notches were 
obtained from mice by technical staff in the Beatson Institute for Cancer Research animal 
facility. Automated PCR genotyping of mouse strains was undertaken by Transnetyx.  
VilCreErT2;LSLBrafV600E+/-;R26-M2-rtTA+/-;Col1a1-tetO-Dnmt3b1+/- cases (n=13) were 
induced by a single intraperitoneal injection of 80mg/kg tamoxifen and 0.5mg/mL of 
doxycycline hyclate in 1% sucrose (administered ad libitum in the drinking water and changed 
three times weekly). Wild-type DNMT3B (i.e. endogenous expression) controls (n=26) for this 
experiment were either of the same genotype as cases (i.e. VilCreErT2; LSLBrafV600E+/-;R26-M2-
rtTA+/-;Col1a1-tetO-Dnmt3b1+/-), or wild-type for either R26- M2-rtTA or Col1a1-tetO-
Dnmt3b1. Control mice were induced by a single intraperitoneal injection of 80mg/kg tamoxifen, 
but were administered 1% sucrose in the drinking water without the addition of doxycyline. As 
additional controls, “DNMT3B only” mice (n=31) were also generated. “DNMT3B only” 
controls were a mixture of VilCreErT2;R26-M2- rtTA+/-;Col1a1-tetO-Dnmt3b1+/-, induced in 
the same fashion as cases and VilCreErT2; LSLBrafV600E+/-;R26-M2-rtTA+/-;Col1a1-tetO-
Dnmt3b1+/- mice, induced with doxycycline but not tamoxifen. Both “DNMT3B only” control 
genotypes were therefore “Braf wild type”.  
Mice were monitored for clinical signs of illness, including weight loss, hunching and 
pedal pallor (anaemia). Mice were sacrificed when they exhibited >20% weight loss, or exhibited 
two or more clinical signs of illness. Mice were culled by exposure to carbon dioxide gas in a 
rising concentration in accordance with the requirements of the Animals (Scientific Procedures) 
Act 1986. Death was confirmed by confirmation of permanent cessation of the circulation and 
dislocation of the neck. The skin was shaved and prepared with ethanol. The abdomen was then 
opened through a midline laparotomy, and the abdominal viscera carefully inspected for 
evidence of tumour formation or metastatic disease. The stomach was divided at the gastro-
oesophageal junction, and the small intestine dissected from its mesentery from gastro-duodenal 
junction to the ileo-caecal junction. The colon was separately dissected from its mesentery, and 
dissection continued to the pelvis where it was amputated at the anorectal junction. Both the 
small intestine and colon were flushed with PBS, before being opened longitudinally in their 
entirety with iris scissors. Following harvest of intestinal tissues, a full necropsy was undertaken 
to exclude other pathology. For tumour scoring and routine haematoxylin and eosin staining, 
tissues were fixed in Methacarn (60% Methanol, 30% chloroform, 10% glacial acetic acid) for 
20 hours. Thereafter, the intestine and colon were wound into a “Swiss roll” in 10% neutral 
buffered formalin and processed for histology. For immunohistochemistry, the small intestine 
and colon were “pinned out” in a paraffin wax dish containing 10% neutral buffered formalin. 
After 24 hours, the intestine and colon were wound into a “Swiss roll” in 10% neutral buffered 
formalin, and processed for histological analysis by the histology service at the Beatson Institute 
for Cancer Research, Glasgow. 
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism (GraphPad Software Inc. La Jolla, 
California, USA). We used non-parametric tests, such as Mann Whitney U and Kruskal Wallis, 
to avoid making assumptions about the probability distribution of the data. Details of statistical 
tests used in individual experiments are detailed in the respective figure legends. Statistical 
analysis of RNA-sequencing is described in more detail in the description of these methods 
above. Several different statistical tests were used in this manuscript. When comparing 
expression levels, we have selected the Mann-Whitney U test where samples are independent 
and randomly selected from the subpopulation and this also accounts for the complex 
multimodality of the distributions of RNA expression data.  Correlation testing of continuous 
variable was considered using the Pearson correlation test.  Where we have tested the 
significance of cell-cycle stage with BRAF status in vitro, we used the Kruskal-Wallace test - of 
ranked and nominal variables where the normality assumption is not satisfied.  Quantifying 
differential expression in the RNA-sequencing experiment was conducted using CuffDiff. 
 
Data and Software Availability 
RNA-seq and DNA methylation data is available at 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126434 (GSE126434 : secure token 
for access exqpcwyshxsfdgd) 
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